TRVI logo

TRVITrevi Therapeutics Inc

$13.46
$0.06
(0.45%)
Today
Closed $13.46
$0.05
(0.37%)
After Hours
Updated: 07:18 PM EDT
EarningsAug 6
Mkt Cap$1.9B
Vol641,942.00
45

Neutral Sentiment

How do you feel about TRVI?

News
all
press releases
Trevi Therapeutics Is Up 100%, Pivotal bioVenture Adds Anyway. Here's Why That Matters.
Key PointsAdded 296,944 shares of Trevi Therapeutics; estimated buy value ~$3.32 million based on quarterly average price...
Nasdaq News: Markets
News Placeholder
More News
News Placeholder
HC Wainwright Reaffirms Buy Rating for Trevi Therapeutics (NASDAQ:TRVI)
HC Wainwright reaffirmed a "buy" rating and set a $21.00 price target on shares of Trevi Therapeutics in a research note on Wednesday...
MarketBeat
News Placeholder
Trevi Therapeutics Q1 Earnings Call Highlights
Trevi Therapeutics (NASDAQ:TRVI) management used the company's first-quarter 2026 earnings call to outline upcoming clinical milestones for its chronic cough programs and to highlight an expanded cash runway following an April equity offering. Clinical program updates and upcoming trial starts Pres...
MarketBeat
News Placeholder
Trevi Therapeutics (NASDAQ:TRVI) Releases Quarterly Earnings Results, Misses Expectations By $0.02 EPS
Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) released its quarterly earnings data on Tuesday. The company reported ($0.09) EPS for the quarter, missing analysts' consensus estimates of ($0.07...
MarketBeat
News Placeholder
Trevi Therapeutics (TRVI) Expected to Announce Quarterly Earnings on Thursday
Trevi Therapeutics (NASDAQ:TRVI) will be releasing its Q1 2026 earnings after the market closes on Thursday, May 7. (View Earnings Report at...
MarketBeat
News Placeholder
Peregrine Capital Management LLC Lowers Stake in Trevi Therapeutics, Inc. $TRVI
Peregrine Capital Management LLC lowered its position in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) by 18.2% during the 4th quarter, according to its most recent disclosure with...
MarketBeat
News Placeholder
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Consensus Recommendation of "Buy" from Brokerages
Trevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) has been given a consensus recommendation of "Buy" by the twelve ratings firms that are currently covering the firm, Marketbeat.com reports...
MarketBeat
News Placeholder
TRVI Stock’s Five-Day Rally Pushes It To An All-Time High – Here’s What’s Happening
The biotech firm priced its $150 million underwritten public offering at $13 per share, representing a roughly 10% discount from Thursday’s closing price.
Stocktwits
News Placeholder
Trevi Therapeutics (NASDAQ:TRVI) Sees Unusually-High Trading Volume - Still a Buy?
Trevi Therapeutics (NASDAQ:TRVI) Sees Large Volume Increase - Here's Why...
MarketBeat
News Placeholder
D. Boral Capital Reiterates "Buy" Rating for Trevi Therapeutics (NASDAQ:TRVI)
D. Boral Capital reaffirmed a "buy" rating and set a $19.00 price target on shares of Trevi Therapeutics in a report on Friday...
MarketBeat
<
1
2
...
>

Advertisement|Remove ads.